Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Tuesday 01 February, 2022

C4X Discovery

Block listing Return

RNS Number : 1986A
C4X Discovery Holdings PLC
01 February 2022
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Block Listing Return

 

1 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing (excluding the additional block listing applications above and those block listings that have now been cancelled):

 

Name of applicant:

C4X Discovery Holdings plc

Name of scheme:

Warrants

Period of return:

From:

1 July 2021

To:

31 January 2022

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

106,964,288 ordinary shares of £0.01 each in the Company admitted to trading on 6 July 2021

Balance of unallotted securities under scheme(s) from previous return:

106,964,288 ordinary shares

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:   Number of securities issued/allotted under scheme(s) during period:

2,200,000

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

104,764,288

 

Name of contact:

Brad Hoy

Telephone number of contact:

+44 (0)203 198 0027

 

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRSDIFIFEESEDF

a d v e r t i s e m e n t